Coronavirus vaccines - Brighton Biotech

Drug Profile

Coronavirus vaccines - Brighton Biotech

Alternative Names: MERS-CoV vaccine - Brighton; Middle east respiratory syndrome - Brighton; SARS-CoV vaccine - Brighton; Severe acute respiratory syndrome - Brighton

Latest Information Update: 28 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Baylor College of Medicine; Sabin Vaccine Institute; Texas Children's Hospital Center for Vaccine Development
  • Developer Baylor College of Medicine; Sabin Vaccine Institute
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Middle East respiratory syndrome coronavirus; Severe acute respiratory syndrome

Most Recent Events

  • 20 Oct 2015 Brighton Biotech acquires Coronavirus vaccines from Baylor College of Medicine and Sabin Vaccine Institute
  • 20 Oct 2015 Preclinical trials in Middle East respiratory syndrome coronavirus (Prevention) in USA (unspecified route)
  • 20 Oct 2015 Preclinical trials in Severe acute respiratory syndrome (Prevention) in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top